About Concord Biotech Limited IPO
Incorporated in 1984, Concord Biotech is a biopharma company. It is one of the leading global developers and manufacturers of select fermentation-based APIs (Active Pharmaceutical Ingredients) across immunosuppressants and oncology. With a market share of 20%, its products are supplied to over 70 countries, including the USA, Europe, Japan and India, as of 2022. Across India, it is present in 20 states and five union territories.
Concord’s product portfolio consists of 23 API products under the immunosuppressant, anti-bacterial, anti-fungal and oncology category as of 31 March 2023. These products are used by patients undergoing organ transplants, to treat autoimmune disorders, cancer and kidney conditions. Company manufactures its products through its three manufacturing facilities situated in Gujarat. In addition, company markets its products through a portfolio of 27 brands across different categories.
Between FY21 and FY23, company witnessed a 11.4% CAGR growth in its revenue from operations. Meanwhile, its profit margins have consistently stayed above 20% in the last three fiscal years. Moreover, the global small-molecule fermentation-based API market is expected to grow at a CAGR of 3.6% to $14 billion between 2022 and 2026, which could benefit the company.
And now, Concord Biotech Limited is coming out with its initial public offer (IPO). The IPO is entirely an offer for sale wherein existing shareholders of the company will sale more than two crore shares. Further, the company expects the proposed IPO listing will enhance its brand image and visibility. Its shares will be listed on the NSE and the BSE.
Here are key details about the Concord Biotech IPO:
A quick look at Concord Biotech Limited IPO’s strengths, risks and threats
Risks and threats
Concord Biotech Limited IPO details
| Concord Biotech Limited IPO date
According to the offer document filed by the company with the SEBI, the Concord Biotech IPO’s opening date – in other words, the Concord Biotech IPO launch date – will be 4th August 2023. The Concord Biotech IPO closing date is 8th August 2023. After this, investors will be updated about the allotment status on 11th August 2023.
Investors, who have been allotted shares, can expect them to be credited to their demat account on 17th August 2023. The Concord Biotech IPO listing date is 18th August 2023. The listing date is the date on which the shares of a company get listed on the bourses – NSE and BSE.
| Concord Biotech Limited IPO price band
The IPO is an offer for sale as well as a fresh issue. The Concord Biotech IPO price band has been set between ₹ 705 and ₹741 per share. Interested investors can choose a price within this band to apply for the IPO.
The Concord Biotech IPO listing price will be determined on 18th August 2023. The listing price is the price at which a company’s shares debut on the stock exchanges.
| Concord Biotech Limited IPO lot size
The Concord Biotech IPO details have been declared. The Concord Biotech IPO lot size is set at 2 20 shares and an investor can apply for a minimum of 1 lot. Meanwhile, the Concord Biotech IPO issue size is approx ₹ 1,551 crore.
How to apply for the Concord Biotech Limited IPO?
If you are interested in this investment opportunity but unsure how to apply for the Concord Biotech Limited IPO, here we are listing out the steps for you.
When the public issue opens for subscription, one can follow this step-by-step guide on how to apply for the Concord Biotech Limited IPO on Upstox:
How to check the Concord Biotech Limited IPO allotment status?
When the allotment process is completed, you can check the status of your application on the Upstox app. Share allotment is generally done around five to six days after an IPO closes.
Here’s a step-by-step guide on how to check the Concord Biotech Limited IPO allotment status:
Open a demat account with Upstox to apply for the Concord Biotech Limited IPO
To apply for the Concord Biotech Limited IPO, you need to mandatorily have a demat account. A demat account helps you hold the shares you buy in a dematerialised format. If you don’t have a demat account yet, you can open one with Upstox by visiting our website or by downloading the app.
Here is a step-by-step guide on how to open a demat account with Upstox:
This is all it takes to open a demat account with Upstox. Easy and quick, right?
Upstox – trading app to apply for the Concord Biotech Limited IPO
Applying for IPOs with Upstox is extremely easy. The user-friendly interface and top-notch security make Upstox one of the leading trading apps in India.
You can apply for the Concord Biotech Limited IPO on Upstox, provided you have a demat account. As mentioned in the previous section, you can simply follow the steps to open a demat account with Upstox. The biggest advantage is that when you apply for an IPO using your Upstox account, the brokerage charges are zero.
In fact, courtesy of its robust features and minimal charges, Upstox is among the most preferred trading apps. Lakhs of Indians trust Upstox as it is a reliable trading platform that makes IPO applications easy.